DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

5 API Suppliers, 5 Listed Suppliers

5 API Suppliers
5 Listed Suppliers

DEVELOPMENTS

35 Drugs in Development

35 Drugs in Development

FINISHED DOSAGE FORMULATIONS

2 FDF Dossiers, 2 FDA Orange Book

2 FDF Dossiers
2 FDA Orange Book

DIGITAL CONTENT

2 DATA COMPILATION #PharmaFlow, 44 NEWS #PharmaBuzz

media
2 DATA COMPILATION #PharmaFlow
44 NEWS #PharmaBuzz

PATENTS & EXCLUSIVITIES

8 US Patents, 2 US Exclusivities

patents
8 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

35DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1194506-26-7, Hmpl-013, Hmpl013, Fruquintinib [who-dd], Fruquintinib(hmpl-013), 6-(6,7-dimethoxyquinazolin-4-yl)oxy-n,2-dimethyl-1-benzofuran-3-carboxamide

Molecular Formula

C₂₁H₁₉N₃O₅

Molecular Weight

393.4 g/mol

InChI Key

BALLNEJQLSTPIO-UHFFFAOYSA-N

FDA UNII

49DXG3M5ZW

Fruquintinib is an orally available, small molecule inhibitor of vascular endothelial growth factor receptors (VEGFRs), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, fruquintinib inhibits VEGF-induced phosphorylation of VEGFRs 1, 2, and 3 which may result in the inhibition of migration, proliferation and survival of endothelial cells, microvessel formation, the inhibition of tumor cell proliferation, and tumor cell death. Expression of VEGFRs may be upregulated in a variety of tumor cell types.

1 2D Structure

Fruquintinib

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

6-(6,7-dimethoxyquinazolin-4-yl)oxy-N,2-dimethyl-1-benzofuran-3-carboxamide

2.1.2 InChI

InChI=1S/C21H19N3O5/c1-11-19(20(25)22-2)13-6-5-12(7-16(13)28-11)29-21-14-8-17(26-3)18(27-4)9-15(14)23-10-24-21/h5-10H,1-4H3,(H,22,25)

2.1.3 InChI Key

BALLNEJQLSTPIO-UHFFFAOYSA-N

2.1.4 Canonical SMILES

CC1=C(C2=C(O1)C=C(C=C2)OC3=NC=NC4=CC(=C(C=C43)OC)OC)C(=O)NC

2.2 Other Identifiers

2.2.1 UNII

49DXG3M5ZW

2.3 Synonyms

2.3.1 MeSH Synonyms

1. Hmpl-013

2.3.2 Depositor-Supplied Synonyms

1. 1194506-26-7

2. Hmpl-013

3. Hmpl013

4. Fruquintinib [who-dd]

5. Fruquintinib(hmpl-013)

6. 6-(6,7-dimethoxyquinazolin-4-yl)oxy-n,2-dimethyl-1-benzofuran-3-carboxamide

7. Fruquintinib [usan]

8. 49dxg3m5zw

9. 6-(6,7-dimethoxyquinazolin-4-yloxy)-n,2-dimethylbenzofuran-3-carboxamide

10. 3-benzofurancarboxamide, 6-((6,7-dimethoxy-4-quinazolinyl)oxy)-n,2-dimethyl-

11. 6-[(6,7-dimethoxyquinazolin-4-yl)oxy]-n,2-dimethyl-1-benzofuran-3-carboxamide

12. 6-((6,7-dimethoxyquinazolin-4-yl)oxy)-n,2-dimethylbenzofuran-3-carboxamide

13. Unii-49dxg3m5zw

14. Elunate

15. Fruquintinib [inn]

16. Fruquintinib; Hmpl-013

17. Fruquintinib (hmpl-013)

18. Schembl947183

19. Gtpl9428

20. Hmpl 013

21. Chembl4303214

22. Bcp15692

23. Ex-a2262

24. Nsc801000

25. Nsc829498

26. S5667

27. Who 10348

28. 6-[(6,7-dimethoxy-4-quinazolinyl)oxy]-n,2-dimethyl-3-benzofurancarboxamide

29. Akos026750586

30. Zinc114898570

31. Ccg-268573

32. Cs-5558

33. Db11679

34. Nsc-801000

35. Nsc-829498

36. Sb17123

37. Ncgc00481603-01

38. As-73141

39. Hmpl-013;hmpl013;hmpl 013

40. Hy-19912

41. B5864

42. A14393

43. C71641

44. A898991

45. Q27259271

46. B2693-470819

2.4 Create Date

2009-12-15

3 Chemical and Physical Properties

Molecular Formula	C₂₁H₁₉N₃O₅
Molecular Weight	393.4 g/mol
XLogP3	3.4
Hydrogen Bond Donor Count	1
Hydrogen Bond Acceptor Count	7
Rotatable Bond Count	5
Exact Mass	393.13247072 g/mol
Monoisotopic Mass	393.13247072 g/mol
Topological Polar Surface Area	95.7 Å²
Heavy Atom Count	29
Formal Charge	0
Complexity	579
Isotope Atom Count	0
Defined Atom Stereocenter Count	0
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1